CX3CR1 and B-cell chronic lymphocytic leukemia: For the first time, we also report that a small molecule antagonist of CX3CR1 (KAND567) specifically hindered the transition of monocytes into NLCs in CLL and blocked their survival-promoting effect on CLL cells in vitro, leading to tumor cell apoptosis [23].